145 related articles for article (PubMed ID: 1992599)
1. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ
Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
[TBL] [Abstract][Full Text] [Related]
4. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
Beland G
Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
[TBL] [Abstract][Full Text] [Related]
5. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
8. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
9. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
10. Total androgen ablation: Canadian experience.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
[TBL] [Abstract][Full Text] [Related]
11. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
13. Total androgen blockade for metastatic cancer of the prostate.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
[TBL] [Abstract][Full Text] [Related]
14. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
15. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Hucher M; de Gery A; Bertagna C
Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
[No Abstract] [Full Text] [Related]
16. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
17. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG; Coleman SG; Faulds D; Chrisp P
Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
[TBL] [Abstract][Full Text] [Related]
18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
Gaillard-Moguilewsky M
Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]